Document:

EX-10.1

 Exhibit 10.1 

KARYOPHARM THERAPEUTICS INC. 

RESTRICTED STOCK UNIT AGREEMENT 

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the agreement date set forth below (the “Agreement
Date”) between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the participant set forth below (the “Participant”) pursuant to the Company’s 2013 Stock Incentive Plan. The terms and
conditions attached hereto are also a part hereof. 
 Notice of Grant 

 

	I.	Agreement Date 

  

			
	Date:	  	

  

	II.	Participant Information 

  

			
	Participant:	  	
	Participant Address:	  	

  

	III.	Grant Information 

  

			
	Grant Date:	  	
	Number of Restricted Stock Units:	  	

  

	IV.	Vesting Table 

  

			
	 Vesting Date
	  	 Number of Restricted Stock Units that Vest

		  	
		  	

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Agreement Date. 

 

					
	KARYOPHARM THERAPEUTICS INC.	 		  	PARTICIPANT
			
	  
	 		  	  

	 Name:
 Title:
	 		  	Name:

 KARYOPHARM THERAPEUTICS INC. 

Restricted Stock Unit Agreement 

Incorporated Terms and Conditions 

For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 

 

	 	1.	Award of Restricted Stock Units. 

 In consideration of services rendered and to be
rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Agreement and in the Company’s 2013 Stock Incentive Plan (the “Plan”), an award (the
“Award”) with respect to the number of restricted shares units (the “RSUs”) set forth in the Notice of Grant that forms part of this Agreement (the “Notice of Grant”). Each RSU represents the right to
receive one share of common stock, $0.0001 par value per share, of the Company (the “Common Stock”) upon vesting of the RSU, subject to the terms and conditions set forth herein. 

 

	 	2.	Vesting. 

 The RSUs shall vest in accordance with the vesting table set forth in the
Notice of Grant (the “Vesting Table”). Upon the vesting of the RSU, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to
Section 7. The Common Stock will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date. 
  

	 	3.	Forfeiture of Unvested RSUs Upon Cessation of Service. 

 (a) Except as otherwise provided
in Section 3(b) hereof, in the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without Cause (as defined in the Plan), all of the RSUs that are unvested as of the time of such cessation
shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation. The Participant shall have no further rights with respect to the unvested RSUs or any
Common Stock that may have been issuable with respect thereto. If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall be deemed to include service with such
subsidiary. 
 (b) In the event that the Participant’s employment is terminated by the Company without Cause before the First Vesting
Date (as defined in the Notice of Grant), the number of RSUs that would have vested on the First Vesting Date shall immediately vest in full on the Participant’s date of termination. In the event that the Participant’s employment is
terminated by the Company without Cause after the First Vesting Date but before the Second Vesting Date (as defined in the Notice of Grant), fifty percent (50%) of the RSUs that would have vested on the Second Vesting Date shall immediately
vest in full on the Participant’s date 

 
of termination. Upon the vesting of the RSUs as described in this Section 3(b), the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock,
subject to the payment of any taxes pursuant to Section 7. The Common Stock will be delivered to the Participant as soon as practicable following the Participant’s date of termination, but in any event within 30 days of such date. 

 

	 	4.	Restrictions on Transfer. 

 The Participant shall not sell, assign, transfer, pledge,
hypothecate or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any
transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement. 
  

	 	5.	Rights as a Shareholder. 

 The Participant shall have no rights as a stockholder of the
Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs. 

 

	 	6.	Provisions of the Plan. 

 This Agreement is subject to the provisions of the Plan
(including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this Agreement. 
  

	 	7.	Tax Matters. 

 (a) Acknowledgments; No Section 83(b) Election. The
Participant acknowledges that he or she is responsible for obtaining the advice of the Participant’s own tax advisors with respect to the Award, and the Participant is relying solely on such advisors and not on any statements or representations
of the Company or any of its agents with respect to the tax consequences relating to the RSUs. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s tax liability that may arise in
connection with the acquisition, vesting and/or disposition of the RSUs. The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”), is available with respect
to RSUs. 
 (b) Withholding. The Participant acknowledges and agrees that the Company has the right to deduct from payments of any
kind otherwise due to the Participant any U.S. federal, state or local taxes, any non-U.S. taxes or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs. At such time as the Participant is not aware of any
material nonpublic information about the Company or the Common Stock, the Participant shall execute the instructions set forth in Schedule A attached hereto (the “Automatic Sale Instructions”) as the means of satisfying such
tax obligation. If the Participant does not execute the Automatic Sale Instructions prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of
the Award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company. The Company shall not 

  
 - 2 - 

 
deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made. If the Participant provides services to a subsidiary of the Company, any
references in this Section 7 and Schedule A to the Company shall be deemed to also refer to such subsidiary. 
  

	 	8.	Miscellaneous. 

 (a) Authority of Compensation Committee. In making any decisions
or taking any actions with respect to the matters covered by this Agreement, the Compensation Committee of the Company’s Board of Directors shall have all of the authority and discretion, and shall be subject to all of the protections, provided
for in the Plan. All decisions and actions by the Compensation Committee with respect to this Agreement shall be made in the Compensation Committee’s discretion and shall be final and binding on the Participant. 

(b) No Right to Continued Service. The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs
is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a
continued service relationship with the Company. 
 (c) Section 409A. The RSUs awarded pursuant to this Agreement are intended to
be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (“Section 409A”). The delivery of shares of Common Stock on the vesting of the RSUs may not be
accelerated or deferred unless permitted or required by Section 409A. 
 (d) Data Privacy. The Participant hereby explicitly and
unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal data as described in this Agreement by and among, as applicable, his or her employer or contracting party and the Company for the
exclusive purpose of implementing, administering and managing his or her participation in the Plan. 
 The Participant understands that the
Company holds certain personal information about him or her, including, but not limited to, his or her name, home address and telephone number, work location and phone number, date of birth, hire date, details of all RSUs awarded, cancelled, vested,
unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (“Personal Data”). The Participant understands that Personal Data may be transferred to any third parties
assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Participant’s country or elsewhere, and that the recipient’s country may have different data privacy laws and
protections than the Participant’s country. The Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Personal Data by contacting his or her local human resources
representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing his or her participation in the
Plan, including any requisite transfer of such Personal Data as may be required to a broker or other third party with whom the Participant may elect to deposit any Common Stock acquired 

  
 - 3 - 

 
upon vesting of the RSUs or in connection with the Participant’s execution of the Automatic Sale Instructions and the sale of the Participant’s Common Stock pursuant to Schedule
A. The Participant understands that Personal Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan. The Participant understands that he or she may, at any time, view Personal
Data, request additional information about the storage and processing of Personal Data, require any necessary amendments to Personal Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local
human resources representative. The Participant understands, however, that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan. For more information on the consequences of Participant’s refusal to
consent or withdrawal of consent, the Participant understands that he or she may contact his or her local human resources representative. For purposes of this Section 8(d), if the Participant provides services to a subsidiary of the Company,
any references in this Section 8(d) to the Company shall be deemed to also refer to such subsidiary. 
 (e) Participant’s
Acknowledgements. The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has received and read a copy of the Plan; (iii) has been represented in the preparation, negotiation and execution of this Agreement
by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iv) understands and agrees to comply with the terms and consequences of this Agreement and the Plan; and (v) is fully aware of the
legal and binding effect of this Agreement. 
 (f) Governing Law. This Agreement shall be construed, interpreted and enforced in
accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions. 

  
 - 4 - 

 Schedule A 

Automatic Sale Instructions 
 The
undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of RSUs on such date shall be paid through an automatic sale of shares as follows: 

(a) Upon any vesting of RSUs pursuant to Section 2 hereof, the Company shall sell, or arrange for the sale of, such number of shares of
Common Stock issuable with respect to the RSUs that vest pursuant to Section 2 as is sufficient to generate net proceeds sufficient to satisfy the Company’s minimum statutory withholding obligations with respect to the income recognized by
the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income) (an “Automatic Tax Sale”), and the Company
shall retain such net proceeds in satisfaction of such tax withholding obligations. 
 (b) The Participant hereby appoints the General
Counsel of the Company as his attorney-in-fact to sell the Participant’s Common Stock in accordance with this Schedule A. The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required
in connection with the sale of the shares pursuant to this Schedule A. If the Company does not have a General Counsel immediately prior to an Automatic Tax Sale, then the Participant hereby appoints the Company’s principal financial officer as
his attorney-in-fact to sell the Participant’s Common Stock in accordance with this Schedule A. 
 (c) The Participant represents to the
Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock. The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a
“binding contract” relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. 

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been
made. 
  

	
	PARTICIPANT
	
	   

	 Name:

	 Date:EX-10.2

 Exhibit 10.2 

KARYOPHARM THERAPEUTICS INC. 

September 18, 2015 
 Christopher B. Primiano 

c/o Karyopharm Therapeutics Inc. 
 85 Wells Avenue 

Newton, MA 02459 
 Dear Chris: 

Subject to your execution below, this letter hereby amends the offer letter, dated March 3, 2014, between you and Karyopharm
Therapeutics Inc. (the “Company”), which was previously amended and restated on January 23, 2015, and provides for the following terms of employment: 

The terms of your position with the Company are as set forth below: 

1. Position. Effective September 18, 2015, your title will change to Senior Vice President, Corporate Development, General
Counsel and Secretary, reporting to the Company’s Chief Executive Officer. In your role you will have the responsibilities customarily associated with such position and those that are assigned to you by the Company’s Chief Executive
Officer. During the term of your employment with the Company, you will devote your full professional time and efforts to the business of the Company, except that you may engage in other activities that may be approved in advance by the
Company’s Board of Directors (the “Board”).
 2. Compensation. 

a. Base Salary. Effective September 18, 2015, you will be paid an annualized gross base salary of Three Hundred
Fifty-Five Thousand Dollars ($355,000), subject to tax and other withholdings required by law. Your base salary will be payable pursuant to the Company’s regular payroll policy. Your salary may be adjusted from time to time in accordance with
normal business practices and in the sole discretion of the Company. 
 b. Bonus Program. You will continue to be
eligible for an annual bonus that targets forty percent (40%) of your annualized base salary based upon achievement of certain performance goals and corporate milestones established by the Company. Achievement of goals will be determined in the
sole discretion of the Board of Directors of the Company (the “Board”) or a Compensation Committee of the Board. To earn any part of the bonus, you must be employed on December 31st
of the applicable bonus year. Your bonus target may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. 

c. Option Grants. We will recommend to the Company’s Board of Directors (or committee thereof) that they grant you
an additional stock option to purchase 75,000 (seventy-five thousand) shares of the Company’s Common Stock at a price per share equal to the fair market value per share of the Common Stock on the date of grant, as determined by the
Company’s Board of Directors (or committee thereof). You are eligible for additional equity grants in the Company’s sole discretion. 

 d. Severance Compensation. If the Company (which, for the purposes of this
paragraph, includes any successor entity) terminates the term of your employment without Cause, or you resign for Good Reason, the Company will continue to pay you your base compensation at its then-current rate, in accordance with the
Company’s then-current regular payroll procedures for employees, for at least six (6) months (subject to upward adjustment in the event that standardized severance terms are authorized for all employees of your level and such terms exceed
the severance amount provided herein) following the date of such termination, provided that you execute a release of any and all claims that you may have against the Company arising from your employment with the Company, reasonably satisfactory to
the Company in form and substance. Additionally, provided you elect to continue your and your eligible dependents’ participation in the Company’s medical and dental benefit plans pursuant to the Consolidated Omnibus Budget Reconciliation
Act of 1986 (“COBRA”), the Company will pay the monthly premium to continue such coverage for the lesser of the six (6) full calendar months immediately following the month in which the termination of your employment occurs and the
end of the calendar month in which you become eligible to receive group health plan coverage under another employee benefit plan. Notwithstanding the foregoing, if your employment is terminated without Cause, or you resign for Good Reason, within
one year following the consummation of a Change in Control (as defined below), then the Company (or its successor entity) will continue to pay you your base compensation at its then-current rate, in accordance with the Company’s (or
successor’s) then-current regular payroll procedures for employees, for at least twelve (12) months following the date of such termination, provided that you execute a release of any and all claims that you may have against the Company (or
its successor) arising from your employment with the Company and/or its successor, reasonably satisfactory to the Company or its successor in form and substance. Additionally, provided you elect to continue your and your eligible dependents’
participation in the Company’s medical and dental benefit plans pursuant to COBRA, the Company will pay the monthly premium to continue such coverage for the lesser of the twelve (12) full calendar months immediately following the month in
which the termination of your employment occurs and the end of the calendar month in which you become eligible to receive group health plan coverage under another employee benefit plan. For purposes of this Offer Letter, “Change in
Control” shall mean the sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a transaction in which all or
substantially all of the individuals and entities who were beneficial owners of the capital stock of the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities (on an
as-converted to Common Stock basis) entitled to vote generally in the election of directors of the (i) resulting, surviving or acquiring corporation in such transaction in the case of a merger, consolidation or sale of outstanding shares, or
(ii) acquiring corporation in the case of a sale of assets. 

 “Cause” shall mean (i) an act or acts of material willful
misconduct by you in violation of law or government regulation in the course of your employment by the Company, (ii) your conviction by a court of competent jurisdiction of theft or misappropriation by you of assets of the Company,
(iii) your conviction by a court of competent jurisdiction of fraud committed by you or at your direction, (iv) your conviction by a court of competent jurisdiction of, or pleading “guilty” or “no contest” to,
(x) a felony or (y) any other criminal charge that has, or could be reasonably expected to have, a material adverse impact on the Company or the performance of your duties, (v) willful, repeated and material failure to perform, or
gross negligence in the performance of, the duties which are reasonably assigned to you by the Company, (vi) material breach of any agreement to which you and the Company are party and/or (vii) failure to fully participate in a Company
investigation as may be reasonably requested by the Company; provided, however, that you shall have a period of thirty (30) days to cure (if curable) any act constituting Cause under clauses (v) or (vii) of this paragraph, following
the Company’s delivery to you of written notice, setting forth in reasonable detail the facts and circumstances claimed to provide a basis for the termination for Cause. 

“Good Reason” shall mean (i) the assignment to you of any duties inconsistent in any adverse, material
respect with your position, authority, duties or responsibilities as then constituted, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, (ii) a reduction in the
aggregate of your base or incentive compensation by greater than ten percent (10%) or the termination of your rights to any employee benefits, except to the extent that any such benefit is replaced with a comparable benefit, or a reduction in
scope or value thereof, other than as a result of across-the-board reductions or terminations affecting employees of the Company generally, or (iii) a requirement that you, without your prior consent, regularly report to work at a location that
is thirty (30) miles or more away from your then current place of work; provided, however, that the conditions described immediately above in clauses (i) through (iii) shall not give rise to a termination for Good
Reason, unless you have notified the Company in writing within thirty (30) days of the first occurrence of the facts and circumstances claimed to provide a basis for the termination for Good Reason, the Company has failed to correct the
condition within fifteen (15) days after the Company’s receipt of such written notice, and you actually terminate employment with the Company within forty-five (45) days of the first occurrence of the condition. For the avoidance of
doubt, your required travel on the Company’s business shall not be deemed a relocation of your principal office under clause (iii), above. 

e. Withholding. The Company shall withhold from any compensation or benefits payable under this letter agreement any
federal, state and local income, employment or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation. 

4. Benefits. 

a. Vacation and Holidays. You will be eligible for a maximum of 20 days of paid vacation each year and Company paid
holidays consistent with the Company’s vacation policy (including accrual of vacation days). 

 b. Other. You will be eligible to participate in such medical, retirement
and other benefits as are approved by the Board and made available to other employees of the Company. 
 As is the case with all employee
benefits, such benefits will be governed by the terms and conditions of applicable plans or policies, which are subject to change or discontinuation at any time. 

5. At-Will Employment. Your employment with the Company is and shall at all times during your employment hereunder be
“at-will” employment. The Company or you may terminate your employment at any time for any reason, with or without cause, and with or without notice. The “at-will” nature of your employment shall remain unchanged during your
tenure as an employee of the Company, and may only be changed by an express written agreement that is signed by you and the Company. 
 6.
Employee Confidentiality Agreement. As an employee of the Company, you will have access to certain Company and third party confidential information and you may during the course of your employment develop certain information or inventions
which will be the property of the Company. You acknowledge the continuing effectiveness of the Nondisclosure and Inventions Assignment Agreement between you and the Company, dated March 17, 2014. 

7. Resolution of Disputes. Any controversy or claim arising out of or relating to your employment, this letter agreement, its
enforcement or interpretation, or because of an alleged breach, default, or misrepresentation in connection with any of its provisions, shall be submitted to arbitration in Boston, Massachusetts before a single arbitrator (applying Massachusetts
law), in accordance with the National Rules for the Resolution of Employment Disputes then in effect of the American Arbitration Association (“AAA”) as modified by the terms and conditions of this Section 7; provided,
however, that provisional injunctive relief may, but need not, be sought in a court of law while arbitration proceedings are pending, and any provisional injunctive relief granted by such court shall remain effective until the matter is
finally determined by the arbitrator. The arbitrator shall be selected by mutual agreement of the parties or, if the parties cannot agree, by striking from a list of arbitrators supplied by AAA. The arbitrator shall issue a written opinion
revealing, however briefly, the essential findings and conclusions upon which any award is based. Final resolution of any dispute through arbitration may include any remedy or relief which the arbitrator deems just and equitable. Any award or relief
granted by the arbitrator hereunder shall be final and binding on the parties hereto and may be enforced by any court of competent jurisdiction. 

The parties acknowledge that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of
the parties against the other in connection with any matter whatsoever arising out of or in any way connected with this letter agreement or your employment. 

The arbitrator shall have the sole and exclusive power and authority to decide any and all issues of or related to whether this letter
agreement or any provision of this letter agreement is subject to arbitration. 

 8. No Inconsistent Obligations. By accepting this offer of employment, you
represent and warrant to the Company that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this letter agreement or that would be violated by your employment by
the Company. You agree that you will not take any action on behalf of the Company or cause the Company to take any action that will violate any agreement that you have with a prior employer. 

9. Miscellaneous. 

a. This letter agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of
which together will constitute one and the same instrument. 
 b. The Company may only assign this letter agreement to a
successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, provided, that such successor expressly agrees to assume and perform this letter
agreement in the same manner and to the same extent that the Company would have been required to perform it if no such assignment had taken place, and “Company” shall include any such successor that assumes and agrees to perform this
letter agreement, by operation of law or otherwise. 
 c. No provision of this letter agreement may be modified, waived or
discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or
provision of this letter agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. 

10. Section 409A. It is intended that this letter agreement comply with or be exempt from Section 409A of the Internal
Revenue Code of 1986, and the Treasury Regulations and IRS guidance thereunder (collectively referred to as “Section 409A”), and notwithstanding anything to the contrary herein, it shall be administered, interpreted, and construed in a
manner consistent with Section 409A. To the extent that any reimbursement, fringe benefit, or other, similar plan or arrangement in which you participate provides for a “deferral of compensation” within the meaning of
Section 409A, (a) the amount of expenses eligible for reimbursement provided to you during any calendar year shall not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to you in any other calendar year,
(b) the reimbursements for expenses for which you are entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred, (c) the right to payment
or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit, and (d) the reimbursements shall be made pursuant to objectively determinable and nondiscretionary Company policies and procedures
regarding such reimbursement of expenses. If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this letter agreement on account of termination of your employment shall be made unless and
until you incur a “separation from service” within the meaning of Section 409A. In the case of any amounts payable to you under this letter agreement that may be treated as payable in the form of “a series of installment
payments”, as defined in Treasury Regulation 

 
Section 1.409A-2(b)(2)(iii), your right to receive such payments shall be treated as a right to receive a series of separate payments for purposes of such Treasury Regulation. If any
paragraph of this letter agreement provides for payment within a time period, the determination of when such payment shall be made within such time period shall be solely in the discretion of the Company. 

11. The validity, interpretation, construction and performance of this letter agreement shall be governed by the laws of the
Commonwealth of Massachusetts without regard to the choice of law principles thereof. 
 [Signatures appear on following page] 

 
			
	Sincerely,
	
	KARYOPHARM THERAPEUTICS INC.
		
	By:	 	/s/ Justin A. Renz
		 	Name: Justin A. Renz
		 	Title: EVP, CFO

  

			
	 I hereby agree to the foregoing

terms of employment:

		
	Agreed:	 	/s/ Christopher B. Primiano
		 	Christopher B. Primiano
		
	Date:	 	September 23, 2015

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]